FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013794057> ?p ?o ?g. }

• W2013794057 abstract "You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness II1 Apr 2012288 COST-EFFECTIVENESS OF SACRAL NEUROMODULATION IN REFRACTORY OVERACTIVE BLADDER A CANADIAN PERSPECTIVE Magdy Hassouna, Jacques Corcos, Neil Dwyer, Jerzy Gajewski, gary Gray, Magali Robert, Le-mai Tu, and Hamid Sadri Magdy HassounaMagdy Hassouna Toronto, Canada More articles by this author , Jacques CorcosJacques Corcos Montreal, Canada More articles by this author , Neil DwyerNeil Dwyer Moncton, Canada More articles by this author , Jerzy GajewskiJerzy Gajewski Dalhousie, Canada More articles by this author , gary Graygary Gray Calgary, Canada More articles by this author , Magali RobertMagali Robert Calgary, Canada More articles by this author , Le-mai TuLe-mai Tu Sherbrooke, Canada More articles by this author , and Hamid SadriHamid Sadri Toronto, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.346AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Refractory overactive bladder (OAB) with urgency incontinence is an underdiagnosed condition with substantial burden on the healthcare system and diminished patient's quality of life. A significant number of patients will fail conservative treatment with optimized medical therapy (OMT) and may benefit from minimally invasive procedures including sacral neuromodulation (SNM) or botulinum toxin (BonT-A) injection. The goal of this study was to estimate the cost-effectiveness of SNM vs. OMT and BonT-A. METHODS An economic Markov model with Monte Carlo simulation was used to assess the incremental cost-effectiveness ratio (ICER) of SNM vs. BonT-A and OMT. The model calculated the ICER in deterministic (base-case) and probabilistic (sensitivity) analysis from a Canadian provincial payer's perspective over a 10-year time horizon with 9-month Markov cycles. Clinical data, healthcare resource utilization and utility scores were acquired from recent publications and an expert panel of 7 Canadian surgeons. Cost data (2011-Dollars) were derived from provincial health insurance policy, drug benefit formulary, and hospital data. All cost and outcomes were discounted at 3% rate. RESULTS The annual (year 1-10) incremental Quality-Adjusted Life Years (QALY) for SNM vs. BonT-A was 0.05-0.51 and SNM vs. OMT was 0.19-1.76. The annual incremental cost of SNM vs. BonT-A was $7,237 in year-1 and -$9,402 in year-10 and was between $8,878 to -$11,447 vs. OMT. In the base-case deterministic analysis, the ICER for SNM vs. BonT-A and OMT were within the acceptable range ($44,837 and $15,130 respectively) at the second year of treatment, with SNM being dominant in the consequent years. In the base-case analysis the probability of ICER being below the acceptability curve (Willingness-To-Pay = $50,000) in Canada was >99% for SNM vs. BonT-A at year 3 and >95% for OMT at year 2. CONCLUSIONS Sacral neuromodulation is a cost-effective treatment option for the management of patients with refractory overactive bladder when compared to either botolinum toxin or optimal medical therapy. From a Canadian payers' perspective, sacral neuromodulation should be considered as first line treatment option in patients with overactive bladder. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e117 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Magdy Hassouna Toronto, Canada More articles by this author Jacques Corcos Montreal, Canada More articles by this author Neil Dwyer Moncton, Canada More articles by this author Jerzy Gajewski Dalhousie, Canada More articles by this author gary Gray Calgary, Canada More articles by this author Magali Robert Calgary, Canada More articles by this author Le-mai Tu Sherbrooke, Canada More articles by this author Hamid Sadri Toronto, Canada More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ..." @default.
• W2013794057 created "2016-06-24" @default.
• W2013794057 creator A5011107887 @default.
• W2013794057 creator A5014206438 @default.
• W2013794057 creator A5020736798 @default.
• W2013794057 creator A5031197355 @default.
• W2013794057 creator A5037380294 @default.
• W2013794057 creator A5037883759 @default.
• W2013794057 creator A5039943874 @default.
• W2013794057 creator A5040665415 @default.
• W2013794057 date "2012-04-01" @default.
• W2013794057 modified "2023-09-24" @default.
• W2013794057 title "288 COST-EFFECTIVENESS OF SACRAL NEUROMODULATION IN REFRACTORY OVERACTIVE BLADDER A CANADIAN PERSPECTIVE" @default.
• W2013794057 doi "https://doi.org/10.1016/j.juro.2012.02.346" @default.
• W2013794057 hasPublicationYear "2012" @default.
• W2013794057 type Work @default.
• W2013794057 sameAs 2013794057 @default.
• W2013794057 citedByCount "1" @default.
• W2013794057 countsByYear W20137940572014 @default.
• W2013794057 crossrefType "journal-article" @default.
• W2013794057 hasAuthorship W2013794057A5011107887 @default.
• W2013794057 hasAuthorship W2013794057A5014206438 @default.
• W2013794057 hasAuthorship W2013794057A5020736798 @default.
• W2013794057 hasAuthorship W2013794057A5031197355 @default.
• W2013794057 hasAuthorship W2013794057A5037380294 @default.
• W2013794057 hasAuthorship W2013794057A5037883759 @default.
• W2013794057 hasAuthorship W2013794057A5039943874 @default.
• W2013794057 hasAuthorship W2013794057A5040665415 @default.
• W2013794057 hasConcept C112930515 @default.
• W2013794057 hasConcept C126322002 @default.
• W2013794057 hasConcept C126894567 @default.
• W2013794057 hasConcept C142724271 @default.
• W2013794057 hasConcept C204787440 @default.
• W2013794057 hasConcept C24998067 @default.
• W2013794057 hasConcept C2778941218 @default.
• W2013794057 hasConcept C2780375056 @default.
• W2013794057 hasConcept C3017551082 @default.
• W2013794057 hasConcept C3019080777 @default.
• W2013794057 hasConcept C71924100 @default.
• W2013794057 hasConceptScore W2013794057C112930515 @default.
• W2013794057 hasConceptScore W2013794057C126322002 @default.
• W2013794057 hasConceptScore W2013794057C126894567 @default.
• W2013794057 hasConceptScore W2013794057C142724271 @default.
• W2013794057 hasConceptScore W2013794057C204787440 @default.
• W2013794057 hasConceptScore W2013794057C24998067 @default.
• W2013794057 hasConceptScore W2013794057C2778941218 @default.
• W2013794057 hasConceptScore W2013794057C2780375056 @default.
• W2013794057 hasConceptScore W2013794057C3017551082 @default.
• W2013794057 hasConceptScore W2013794057C3019080777 @default.
• W2013794057 hasConceptScore W2013794057C71924100 @default.
• W2013794057 hasIssue "4S" @default.
• W2013794057 hasLocation W20137940571 @default.
• W2013794057 hasOpenAccess W2013794057 @default.
• W2013794057 hasPrimaryLocation W20137940571 @default.
• W2013794057 hasRelatedWork W1548025074 @default.
• W2013794057 hasRelatedWork W1978157296 @default.
• W2013794057 hasRelatedWork W2045518046 @default.
• W2013794057 hasRelatedWork W2129403191 @default.
• W2013794057 hasRelatedWork W2206285582 @default.
• W2013794057 hasRelatedWork W2320912658 @default.
• W2013794057 hasRelatedWork W2588319390 @default.
• W2013794057 hasRelatedWork W2739238305 @default.
• W2013794057 hasRelatedWork W4233141978 @default.
• W2013794057 hasRelatedWork W4282032847 @default.
• W2013794057 hasVolume "187" @default.
• W2013794057 isParatext "false" @default.
• W2013794057 isRetracted "false" @default.
• W2013794057 magId "2013794057" @default.
• W2013794057 workType "article" @default.